J Siddiqui1, F Bala1, S Sciacca2, A M Falzon2, M Benger3, S A Matloob4, F N A C Miller5, R J Simister6,7, I Chatterjee6, L K Sztriha3, I Davagnanam2,8, T C Booth9,10. 1. From the Departments of Neuroradiology (J.S., F.B., T.C.B.). 2. Lysholm Department of Neuroradiology (S.S., A.M.F., I.D.). 3. Neurology (M.B., L.K.S.). 4. Department of Neurosurgery (S.A.M.), National Hospital for Neurology and Neurosurgery, University College London Hospitals, National Health Service Foundation Trust, London, UK. 5. Radiology (F.N.A.C.M.), King's College Hospital, National Health Service Foundation Trust, London, UK. 6. Comprehensive Stroke Service (R.J.S., I.C.), University College London Hospitals, National Health Service Foundation Trust, London, UK. 7. Stroke Research Centre (R.J.S.). 8. Brain Repair and Rehabilitation Unit (I.D.), University College London Queen Square Institute of Neurology, London, UK. 9. From the Departments of Neuroradiology (J.S., F.B., T.C.B.) thomas.booth@kcl.ac.uk. 10. School of Biomedical Engineering and Imaging Sciences (T.C.B.), King's College London, Rayne Institute, St. Thomas' Hospital, London, UK.
Abstract
BACKGROUND AND PURPOSE: Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction testing, but the sensitivity is limited. Carotid CTA is a routine acute stroke investigation and includes the lung apices. We evaluated CTA as a potential COVID-19 diagnostic imaging biomarker. MATERIALS AND METHODS: This was a multicenter, retrospective study (n = 225) including CTAs of patients with suspected acute stroke from 3 hyperacute stroke units (March-April 2020). We evaluated the reliability and accuracy of candidate diagnostic imaging biomarkers. Demographics, clinical features, and risk factors for COVID-19 and stroke were analyzed using univariate and multivariate statistics. RESULTS: Apical ground-glass opacification was present in 22.2% (50/225) of patients. Ground-glass opacification had high interrater reliability (Fleiss κ = 0.81; 95% CI, 0.68-0.95) and, compared with reverse-transcriptase polymerase chain reaction, had good diagnostic performance (sensitivity, 75% [95% CI, 56-87]; specificity, 81% [95% CI, 71-88]; OR = 11.65 [95% CI, 4.14-32.78]; P < .001) on multivariate analysis. In contrast, all other contemporaneous demographic, clinical, and imaging features available at CTA were not diagnostic for COVID-19. The presence of apical ground-glass opacification was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .017; hazard ratio = 3.51; 95% CI, 1.42-8.66; P = .006). CONCLUSIONS: We identified a simple, reliable, and accurate COVID-19 diagnostic and prognostic imaging biomarker obtained from CTA lung apices: the presence or absence of ground-glass opacification. Our findings have important implications in the management of patients presenting with suspected stroke through early identification of COVID-19 and the subsequent limitation of disease transmission.
BACKGROUND AND PURPOSE: Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction testing, but the sensitivity is limited. Carotid CTA is a routine acute stroke investigation and includes the lung apices. We evaluated CTA as a potential COVID-19 diagnostic imaging biomarker. MATERIALS AND METHODS: This was a multicenter, retrospective study (n = 225) including CTAs of patients with suspected acute stroke from 3 hyperacute stroke units (March-April 2020). We evaluated the reliability and accuracy of candidate diagnostic imaging biomarkers. Demographics, clinical features, and risk factors for COVID-19 and stroke were analyzed using univariate and multivariate statistics. RESULTS: Apical ground-glass opacification was present in 22.2% (50/225) of patients. Ground-glass opacification had high interrater reliability (Fleiss κ = 0.81; 95% CI, 0.68-0.95) and, compared with reverse-transcriptase polymerase chain reaction, had good diagnostic performance (sensitivity, 75% [95% CI, 56-87]; specificity, 81% [95% CI, 71-88]; OR = 11.65 [95% CI, 4.14-32.78]; P < .001) on multivariate analysis. In contrast, all other contemporaneous demographic, clinical, and imaging features available at CTA were not diagnostic for COVID-19. The presence of apical ground-glass opacification was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .017; hazard ratio = 3.51; 95% CI, 1.42-8.66; P = .006). CONCLUSIONS: We identified a simple, reliable, and accurate COVID-19 diagnostic and prognostic imaging biomarker obtained from CTA lung apices: the presence or absence of ground-glass opacification. Our findings have important implications in the management of patients presenting with suspected stroke through early identification of COVID-19 and the subsequent limitation of disease transmission.
Authors: Riti Kanesa-Thasan; Mougnyan Cox; Manisha Patel; Brian Curtis; Robert W Hurst; David Kung; Adam E Flanders Journal: Neuroradiol J Date: 2018-09-21
Authors: Adam Bernheim; Xueyan Mei; Mingqian Huang; Yang Yang; Zahi A Fayad; Ning Zhang; Kaiyue Diao; Bin Lin; Xiqi Zhu; Kunwei Li; Shaolin Li; Hong Shan; Adam Jacobi; Michael Chung Journal: Radiology Date: 2020-02-20 Impact factor: 11.105
Authors: Brooks P Applewhite; Karen Buch; Byung Chul Yoon; Min Lang; Matthew D Li; Sandra P Rincon; William A Mehan Journal: Emerg Radiol Date: 2020-07-21
Authors: Ho Yuen Frank Wong; Hiu Yin Sonia Lam; Ambrose Ho-Tung Fong; Siu Ting Leung; Thomas Wing-Yan Chin; Christine Shing Yen Lo; Macy Mei-Sze Lui; Jonan Chun Yin Lee; Keith Wan-Hang Chiu; Tom Wai-Hin Chung; Elaine Yuen Phin Lee; Eric Yuk Fai Wan; Ivan Fan Ngai Hung; Tina Poy Wing Lam; Michael D Kuo; Ming-Yen Ng Journal: Radiology Date: 2020-03-27 Impact factor: 11.105
Authors: J Siddiqui; F Bala; S Sciacca; A M Falzon; M Benger; S A Matloob; F N A C Miller; R J Simister; I Chatterjee; L K Sztriha; I Davagnanam; T C Booth Journal: AJNR Am J Neuroradiol Date: 2020-12-03 Impact factor: 3.825
Authors: F Bala; J Siddiqui; S Sciacca; A M Falzon; M Benger; S A Matloob; F N A C Miller; R J Simister; I Chatterjee; L K Sztriha; I Davagnanam; T C Booth Journal: AJNR Am J Neuroradiol Date: 2021-05-20 Impact factor: 4.966
Authors: Ahmed Yassin; Mohammed Nawaiseh; Ala Shaban; Khalid Alsherbini; Khalid El-Salem; Ola Soudah; Mohammad Abu-Rub Journal: BMC Neurol Date: 2021-03-30 Impact factor: 2.474